Administered by Food and Drug Administration
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development. Grant Number: FOR-FD-25-006. Expected awards: 10.
All of the following criteria must be met:
Grant details are sourced from official public databases and reviewed weekly. Eligibility criteria, funding amounts, and deadlines may change without notice. Always confirm details on the Food and Drug Administration website before applying.
RaftLabs helps established businesses turn funding into working software, loyalty apps, and AI tools.
Talk to RaftLabs →More funding opportunities that may match your business
Air Force Office of Scientific Research
Air Force Defense Research Sciences Conference and Workshop Support offered by Air Force Office of Scientific Research.
ACC-APG-Detrick
Deployed Warfighter Protection (DWFP) Program for the Protection of Deployed Military Personnel from Threats Posed by Arthropod Disease Vectors offered by ACC-APG-Detrick.
U.S. National Science Foundation
Innovations in Graduate Education (IGE) Program offered by U.S. National Science Foundation.